吉非替尼与多西紫杉醇二线治疗Ⅳ期肺腺癌疗效比较  

Gefitinib Versus Docetaxel as Second-line Therapy for Patients with Stage Ⅳ Lung Adenocarcinoma

作　　者：苏安[1] 吕霞[1] 王馨[1] 潘战和[1] 肖莉[1] 

机构地区：[1]厦门大学附属中山医院肿瘤科,361004

出　　处：《实用癌症杂志》2007年第6期617-619,共3页The Practical Journal of Cancer

摘　　要：目的比较吉非替尼与多西紫杉醇二线治疗Ⅳ期肺腺癌的疗效与毒性。方法对60例体力状况评分为0～2分、既往曾行含铂双药方案化疗、脏器功能许可接受化疗的Ⅳ期肺腺癌患者,分别接受吉非替尼250mg/日,口服,或多西紫杉醇75mg/m2,第1天,静脉滴注,每21天为1个周期。结果吉非替尼组和多西紫杉醇组的客观有效率分别为40.0%和10.0%(P<0.05),中位无进展时间分别为6.3和3.1个月,中位生存时间分别为11.5和6.7个月,1年生存率分别为43.3%和26.7%。多西紫杉醇的3～4级粒细胞减少、发热性粒细胞减少、粒细胞集落刺激因子的使用率和脱发显著高于吉非替尼。结论吉非替尼二线治疗Ⅳ期肺腺癌的客观有效率优于多西紫杉醇,且不良反应显著少于多西紫杉醇,可作为晚期肺腺癌患者的二线治疗药物。Objective To compare the efficacy and toxicities of gefitinib versus docetaxel in patients with stage Ⅳ lung adenocarcinoma previously treated with chemotherapy. Methods 60 patients with stage Ⅳ lung adenocarcinoma were included in the study. The eligibility criteria included a performance status of 0 to 2, previous treatment with platinum-based two drug chemotherapy, and adequate organ function. Patients received oral gefitinib 250 mg/day or docetaxel 75 mg/m^2 Ⅳ dayl, repeated every 21 days. Results Overall response rate was 40.0% and 10.0% in the gefitinib and docetaxel group （ P 〈 0.05 ） , respectively. The median progression free survival time was 6.3 months and 3.1 months, and the median survival time was 11.5 versus 6.7 months in the gefitinib and docetaxel group. The 1-year survival rate was 43% and 27% for gefitinib and docetaxel treatment. Patients receiving docetaxel were more likely to have grade 3 or 4 neutropenia,febrile neutropenia,use of granulocyte colony-stimulating factor support and all grade alopecia compared with patients receiving gefitinib. Condusion Treatment with gefitinib resulted in clinically better efficacy outcomes, and with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with stage Ⅳ lung adenocarcinoma and should be considered a treatment option for second-line stage Ⅳ lung adenoearcinoma.

关 键 词：肺腺癌 吉非替尼 多西紫杉醇 

分 类 号：R734.2[医药卫生—肿瘤]